Takahashi, Masanobu
Kato, Ken
Okada, Morihito
Chin, Keisho
Kadowaki, Shigenori
Hamamoto, Yasuo
Doki, Yuichiro
Kubota, Yutaro
Kawakami, Hisato
Ogata, Takashi
Hara, Hiroki
Muto, Manabu
Nakashima, Yuichiro
Ishihara, Ryu
Tsuda, Masahiro
Motoyama, Satoru
Kodani, Mamoru
Kitagawa, Yuko
Funding for this research was provided by:
Ono Pharmaceutical Co., Ltd., Osaka, Japan, and Bristol-Myers Squibb, Princeton, NJ, USA.
Article History
Received: 31 August 2020
Accepted: 23 October 2020
First Online: 10 November 2020
Compliance with ethical standards
:
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.
: Masanobu Takahashi received grants from Ono Pharmaceutical Co., Ltd., during the conduct of the study; and personal fees from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Daiichi Sankyo, and Taiho Pharmaceutical Co., Ltd., outside the submitted work. Ken Kato received grants from Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb K.K. during the conduct of the study; and research funds from MSD K.K., Shionogi & Co. Ltd., BeiGene, Merck Biopharma Co., Ltd, and Oncolys BioPharma, outside the submitted work. Morihito Okada received grants and personal fees from Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb K.K. during the conduct of the study. Yuichiro Doki received grants and personal fees from Ono Pharmaceutical Co., Ltd.; and grants from Bristol-Myers Squibb K.K. during the conduct of the study. Shigenori Kadowaki received grants and personal fees from Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb K.K. during the conduct of the study; and grants and personal fees from Eli Lilly Japan K.K. and Chugai Pharmaceutical Co., Ltd.; personal fees from Bayer Yakuhin, Ltd., Daiichi Sankyo, Yakult Honsha Co., Ltd., Eisai Co., Ltd, and Merck KGaA; and grants from MSD K.K., Nobelpharma Co., Ltd, and Taiho Pharmaceutical Co., Ltd., outside the submitted work. Yasuo Hamamoto, Yutaro Kubota, Keisho Chin, Takashi Ogata, Yuichiro Nakashima, Ryu Ishihara, Masahiro Tsuda, and Satoru Motoyama received grants from Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb K.K. during the conduct of the study. Hisato Kawakami received grants from Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K. during the conduct of the study; grants, personal fees, and other [advisory role, honoraria (speeches)] from Taiho Pharmaceutical Co., Ltd.; grants, personal fees, and other [advisory role, honoraria (speeches), research funding to institution] from Daiichi Sankyo; grants and personal fees (honoraria [speeches], research funding to institution) from Chugai Pharmaceutical Co., Ltd./Roche; personal fees and other [advisory role, honoraria (speeches)] from Bristol-Myers Squibb K.K., Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K.; personal fees (honoraria [speeches]) from Yakult Honsha Co., Ltd., Takeda Pharmaceutical Company Limited, MSD K.K., Merck Serono Co., Ltd, Bayer Yakuhin, Ltd., and AstraZeneca K.K.; and grants (research funding to institution) from Eisai Co., Ltd, outside the submitted work. Hiroki Hara received grants from Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb K.K. during the conduct of the study, and grants from AstraZeneca K.K., Sumitomo Dainippon Pharma Co., Ltd., Merck Biopharma Co., Ltd, Eisai Co., Ltd, LSK BioPharma, Incyte Corporation, Pfizer, Nippon Boehringer Ingelheim Co., Ltd., BeiGene, and Astellas; grants and personal fees from Daiichi Sankyo, MSD K.K., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb K.K.; and personal fees from Eli Lilly Japan K.K., Yakult Honsha Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co., Ltd., outside the submitted work. Manabu Muto received grants from Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb K.K. during the conduct of the study, and grants from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Sysmex Corporation, Riken Genesis, Mitsui Knowledge Inc., and Ono Pharmaceutical Co., Ltd., outside the submitted work. Mamoru Kodani is an employee of Ono Pharmaceutical Co., Ltd. Yuko Kitagawa received grants and personal fees from Asahi Kasei Pharma Corp., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Yakult Honsha Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc., Shionogi & Co., Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Nihon Pharmaceutical Co., Ltd., and Sanofi K.K.; and grants from Daiichi Sankyo Company, Limited, Merck Serono Co., Ltd., Takeda Pharmaceutical Company Limited, Kaken Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Medicon Inc., Kyowa Kirin Co., Ltd., Pfizer Japan Inc., Japan Blood Products Organization, Medtronic Japan Co., Ltd., Eisai Co., Ltd., Tsumura and Co., KCI Licensing, Inc., Abbott Japan Co., Ltd., Fujifilm Toyama Chemical Co., Ltd., Nippon Covidien Inc., outside the submitted work.